Collectively, these two large surveys strongly indicate that partial ANG-PTL3 deficiency due to heterozygosity for LOF Angptl3 variants results in a reduced risk of CAD as compared to non-carriers, suggesting that ANGPTL3 may be a novel target to reduce the level of atherogenic lipoproteins[25–26]. This evidence concerns the gene ANGPTL3 and coronary artery disorder.